生物製藥契約製造市場規模、佔有率和成長分析（按服務、類型、營運規模、原料、分子類型和地區）：產業預測（2025-2032）

2023年全球生物製藥契約製造市場規模為165億美元，從2024年的178.5億美元成長到2032年的335.4億美元，預測期間（2025-2032年）預計複合年成長率為8.2%。

由於開發新藥所需投資的減少、尖端技術的普及以及創新產品的快速進入市場，全球生物製藥契約製造市場預計將大幅成長。尤其是，賽默飛世爾科技最近耗資 1.8 億美元在普萊恩維爾建造的新製造工廠就體現了這一趨勢，可以增強額外的生產能力，以滿足不斷成長的消費者需求。此外，生物加工技術的快速進步正在提高世界各地合約服務提供者的能力，緩解高成本和批次轉換問題等傳統製造挑戰。此外，大公司之間的策略性合併、收購和合資企業正在增加這些服務的潛力，例如 Baxter International 與 Baxter BioPharma Solutions 於 2021 年合作生產 COVID-19 疫苗。

目錄

介紹

• 分析目的
• 市場範圍
• 定義

分析方法

• 資訊採購
• 次要/主要資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考慮因素

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場魅力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究
• FDA認證的生物製藥CMO中心

全球生物製藥契約製造市場規模和複合年成長率：按服務分類（2025-2032）

• 市場概況
• 製造業
• 混煉、填充、整理
• 包裝/標籤
• 其他服務

全球生物製藥契約製造市場規模和複合年成長率：按類型（2025-2032）

• 市場概況
• 生技藥品原料藥成分的製造
• 生技藥品製品製造

全球生物製藥契約製造市場規模及複合年成長率：依營運規模分類（2025-2032）

• 市場概況
• 商業運作
• 臨床管理

全球生物製藥契約製造市場規模和複合年成長率：按原料分類（2025-2032）

• 市場概況
• 哺乳動物細胞表現系統
• 非哺乳動物細胞表現系統

全球生物製藥契約製造市場規模與複合年成長率：按分子類型分類（2025-2032）

• 市場概況
• 單株抗體
• 細胞/基因治療
• 抗體藥物複合體
• 疫苗
• 治療性胜肽和蛋白質
• 其他分子類型

全球生物製藥契約製造市場規模與複合年成長率：按治療領域分類（2025-2032）

• 市場概況
• 腫瘤學
• 自體免疫疾病
• 代謝性疾病
• 心血管疾病
• 神經病學
• 感染疾病
• 其他治療領域

全球生物製藥契約製造市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要企業採取的策略
• 近期市場趨勢
• 主要企業市場佔有率（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• 龍沙（瑞士）
• 賽默飛世爾科技公司（美國）
• 藥明生物（中國）
• 康泰倫特公司（美國）
• 三星生物製品（韓國）
• 勃林格殷格翰國際有限公司（德國）
• 富士膠片控股公司（日本）
• 艾伯維公司（美國）
• Eurofins Scientific（盧森堡）
• 金斯瑞生物科技股份有限公司 (中國)
• AGC公司（日本）
• Merck
• KGaA（德國）
• JSR株式會社（日本）
• Stelis（India）
• Recipharm AB（瑞典）
• 緊急（美國）
• 上海復星醫藥股份有限公司 (中國)
• 樂天生物製品（韓國）
• 海普瑞集團（中國）
• Curia Global, Inc.（美國）

結論和建議

Global Biopharmaceuticals Contract Manufacturing Market size was valued at USD 16.5 billion in 2023 and is poised to grow from USD 17.85 billion in 2024 to USD 33.54 billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The global biopharmaceuticals contract manufacturing market is poised for significant growth, driven by reduced investment needs for new drug development, enhanced access to advanced technologies, and expedited market entry for innovative products. Notably, Thermo Fisher Scientific's recent USD 180 million investment in a new manufacturing facility in Plainville exemplifies this trend, enabling increased production capacity to meet surging consumer demand. Additionally, rapid technological advancements in bioprocessing are alleviating traditional manufacturing challenges, such as high costs and batch changeover issues, boosting the capabilities of contract service providers worldwide. Furthermore, strategic mergers, acquisitions, and joint ventures among key market players are fueling demand for these services, as illustrated by Baxter International's collaboration with Baxter BioPharma Solutions for COVID-19 vaccine production in 2021.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Contract Manufacturing Market Segmental Analysis

Global Biopharmaceuticals Contract Manufacturing Market is segmented by Service, Type, Scale Of Operation, Source, Molecule Type,TherapeuticArea and region. Based on Service, the market is segmented into Manufacturing, Formulation & Fill-Finish, Packaging & Labeling and Other Services. Based on Type, the market is segmented into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing. Based on Scale Of Operation, the market is segmented into Commercial Operations and Clinical Operations. Based on Source, the market is segmented into Mammalian Expression Systems and Non-Mammalian Expression Systems. Based on Molecule Type, the market is segmented into Monoclonal Antibodies, Cell & Gene Therapies, Antibody-Drug Conjugates, Vaccines, Therapeutic Peptides & Proteins and Other Molecule Types. Based on Therapeutic Area, the market is segmented into Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases and Other Therapeutic Areas. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is primarily driven by the surging demand for biological therapies, which is influenced by several key factors. Notably, the continual rise in the demand for generics, coupled with heightened research and development efforts and investments in cutting-edge technologies, is expected to propel market growth during the forecast period. Additionally, the expansion of the nuclear medicine sector and a greater focus on specialty medicines are anticipated to further stimulate market progression. These elements collectively contribute to a promising landscape for the biopharmaceuticals contract manufacturing market in the years ahead.

Restraints in the Global Biopharmaceuticals Contract Manufacturing Market

The global biopharmaceuticals contract manufacturing market is facing several restraints that hinder its growth during the forecast period. Key challenges include labeling and packaging complications, along with sterilization issues that complicate the manufacturing process. Furthermore, a general lack of consumer trust combined with insufficient knowledge regarding the manufacturing processes may further restrict market expansion in the upcoming years. These various associated problems are critical factors that stakeholders need to address in order to facilitate smoother operations and enhance market performance in the highly competitive biopharmaceuticals landscape.

Market Trends of the Global Biopharmaceuticals Contract Manufacturing Market

The Global Biopharmaceuticals Contract Manufacturing market is witnessing a notable trend driven by technological advancements, particularly the integration of artificial intelligence (AI). In recent years, the surge in scientific exploration aimed at addressing critical health challenges has propelled market expansion. AI's burgeoning role in analyzing patient symptoms and facilitating real-time data tracking for disease patterns is revolutionizing manufacturing processes. This technological synergy not only enhances efficiency but also fosters innovation in drug development, leading to improved therapeutic solutions. As a result, stakeholders can anticipate robust growth opportunities in the biopharmaceutical contract manufacturing sector in the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies
• FDA Approved Biopharmaceuticals CMOs Centers

Global Biopharmaceuticals Contract Manufacturing Market Size by Service & CAGR (2025-2032)

• Market Overview
• Manufacturing
• Formulation & Fill-Finish
• Packaging & Labeling
• Other Services

Global Biopharmaceuticals Contract Manufacturing Market Size by Type & CAGR (2025-2032)

• Market Overview
• Biologic Drug Substance Manufacturing
• Biologic Drug Product Manufacturing

Global Biopharmaceuticals Contract Manufacturing Market Size by Scale Of Operation & CAGR (2025-2032)

• Market Overview
• Commercial Operations
• Clinical Operations

Global Biopharmaceuticals Contract Manufacturing Market Size by Source & CAGR (2025-2032)

• Market Overview
• Mammalian Expression Systems
• Non-Mammalian Expression Systems

Global Biopharmaceuticals Contract Manufacturing Market Size by Molecule Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Cell & Gene Therapies
• Antibody-Drug Conjugates
• Vaccines
• Therapeutic Peptides & Proteins
• Other Molecule Types

Global Biopharmaceuticals Contract Manufacturing Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Other Therapeutic Areas

Global Biopharmaceuticals Contract Manufacturing Market Size & CAGR (2025-2032)

• North America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • US
  • Canada
• Europe (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JSR Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stelis (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lotte Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepalink Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations